Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Warner Chilcott 1Q Net Income Holds Steady

By Pharmaceutical Processing | May 10, 2013

Irish drugmaker Warner Chilcott PLC said Friday its net income held steady in the first quarter despite lower sales of some of its biggest products.

The company said sales of its ulcerative colitis drug Asacol fell because it stopped selling one dose of the drug after receiving marketing approval for a newer drug that treats the same condition. Revenue from its osteoporosis drug Actonel continued to fall because of generic competition in Western Europe and Canada.

Warner Chilcott said its net income was unchanged at $113 million, or 45 cents per share. Excluding one-time items the company said it earned 92 cents per share in the latest quarter, down from $1.16 per share a year ago. Its revenue fell 13 percent, to $593 million from $685 million.

Analysts were expecting income of 85 cents per share on $592.2 million in revenue, according to FactSet.

In February the Food and Drug Administration approved the company’s new ulcerative colitis drug Delzicol. Warner Chilcott began marketing Delzicol in March, and it stopped selling 400-milligram doses of Asacol. Revenue from Asacol fell 27 percent to $153 million, and Delzicol sales totaled $5 million. Actonel sales in Western Europe and Canada continued to decrease after patent protection expired, and total sales fell 24 percent to $111 million.

The company said sales oral contraceptives grew 6 percent to $151 million.

Warner Chilcott said it expects to take about $3 million in additional restructuring and litigation costs in 2013, but it maintained its annual net income of revenue forecasts. The company called for adjusted net income of $3.20 to $3.30 per share on revenue of $2.3 billion to $2.4 billion.

Analysts are expecting net income of $3.29 per share and $2.34 billion in revenue, on average.

Shares of Warner Chilcott gained 13 percent, or $1.99, or $17 in midday trading, rallying on a media report that Actavis is in early stages to acquire the company. Bloomberg’s report was based on anonymous sources familiar with the process. Warner Chilcott and Actavis Inc., a Parsippany, N.J.-based maker of generic drugs, both declined to comment on the report.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE